Tags

Type your tag names separated by a space and hit enter

Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients?
Haematologica. 1995 Jul-Aug; 80(4):332-4.H

Abstract

Since fish oil has been reported to reduce platelet aggregability, to reduce blood viscosity by increasing red blood cell deformability and to lower blood pressure, we studied the effect of dietary supplementation with fish oil on the occurrence of adverse effects in patients receiving recombinant human erythropoietin (rHuEPO). In a prospective, randomized, double blind cross-over design we studied the effect of daily ingestion of 3 g fish oil versus 3 g corn oil (placebo) for 5 months, with a wash-out period of 3 months in between. Thirty-two dialysis patients newly treated with rHuEPO participated. rHuEP0 was given using a low and slow dose regimen (25 U/kg twice weekly s.c.). Target Hct was 35%. Blood pressure, red blood cell deformability, plasma viscosity, fatty acid composition of plasma phospholipids, and fibrinogen levels were measured at 0, 5, 8 and 13 months. In both groups a stable target Hct (35%) was reached within 3 months. Blood pressure was not significantly different between the groups at any time point. In 4 patients (2 on fish oil and 2 on placebo) antihypertensives had to be increased to regulate blood pressure adequately, whereas shunt occlusion occurred in one patient on placebo. Despite a significant increase in the omega-3 fatty acid content of plasma phospholipids during ingestion of fish oil, no significant changes in red blood cell deformability were observed. Since hypertension and shunt occlusion occurred at rates comparable to those reported in the literature, long-term ingestion of fish oil does not appear to mitigate the side effects of low and slow dose rHuEPO.

Authors+Show Affiliations

Department of Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7590502

Citation

de Fijter, C W., et al. "Does Additional Treatment With Fish Oil Mitigate the Side Effects of Recombinant Human Erythropoietin in Dialysis Patients?" Haematologica, vol. 80, no. 4, 1995, pp. 332-4.
de Fijter CW, Popp-Snijders C, Oe LP, et al. Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients? Haematologica. 1995;80(4):332-4.
de Fijter, C. W., Popp-Snijders, C., Oe, L. P., Tran, D. D., van der Meulen, J., & Donker, A. J. (1995). Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients? Haematologica, 80(4), 332-4.
de Fijter CW, et al. Does Additional Treatment With Fish Oil Mitigate the Side Effects of Recombinant Human Erythropoietin in Dialysis Patients. Haematologica. 1995 Jul-Aug;80(4):332-4. PubMed PMID: 7590502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Does additional treatment with fish oil mitigate the side effects of recombinant human erythropoietin in dialysis patients? AU - de Fijter,C W, AU - Popp-Snijders,C, AU - Oe,L P, AU - Tran,D D, AU - van der Meulen,J, AU - Donker,A J, PY - 1995/7/1/pubmed PY - 1995/7/1/medline PY - 1995/7/1/entrez SP - 332 EP - 4 JF - Haematologica JO - Haematologica VL - 80 IS - 4 N2 - Since fish oil has been reported to reduce platelet aggregability, to reduce blood viscosity by increasing red blood cell deformability and to lower blood pressure, we studied the effect of dietary supplementation with fish oil on the occurrence of adverse effects in patients receiving recombinant human erythropoietin (rHuEPO). In a prospective, randomized, double blind cross-over design we studied the effect of daily ingestion of 3 g fish oil versus 3 g corn oil (placebo) for 5 months, with a wash-out period of 3 months in between. Thirty-two dialysis patients newly treated with rHuEPO participated. rHuEP0 was given using a low and slow dose regimen (25 U/kg twice weekly s.c.). Target Hct was 35%. Blood pressure, red blood cell deformability, plasma viscosity, fatty acid composition of plasma phospholipids, and fibrinogen levels were measured at 0, 5, 8 and 13 months. In both groups a stable target Hct (35%) was reached within 3 months. Blood pressure was not significantly different between the groups at any time point. In 4 patients (2 on fish oil and 2 on placebo) antihypertensives had to be increased to regulate blood pressure adequately, whereas shunt occlusion occurred in one patient on placebo. Despite a significant increase in the omega-3 fatty acid content of plasma phospholipids during ingestion of fish oil, no significant changes in red blood cell deformability were observed. Since hypertension and shunt occlusion occurred at rates comparable to those reported in the literature, long-term ingestion of fish oil does not appear to mitigate the side effects of low and slow dose rHuEPO. SN - 0390-6078 UR - https://www.unboundmedicine.com/medline/citation/7590502/Does_additional_treatment_with_fish_oil_mitigate_the_side_effects_of_recombinant_human_erythropoietin_in_dialysis_patients L2 - https://medlineplus.gov/kidneyfailure.html DB - PRIME DP - Unbound Medicine ER -